Adial Pharmaceuticals, Inc.
ADIL
$6.44
-$0.21-3.16%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.48M | 5.23M | 5.18M | 5.12M | 5.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.49M | 7.53M | 7.80M | 7.85M | 8.30M |
| Operating Income | -11.49M | -7.53M | -7.80M | -7.85M | -8.30M |
| Income Before Tax | -57.80M | -7.77M | -7.98M | -8.05M | -8.45M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -57.80 | -7.77 | -7.98 | -8.05 | -8.45 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.80M | -7.77M | -7.98M | -8.05M | -8.45M |
| EBIT | -11.49M | -7.53M | -7.80M | -7.85M | -8.30M |
| EBITDA | -11.49M | -7.53M | -7.80M | -7.85M | -8.30M |
| EPS Basic | -16.57 | -9.93 | -16.98 | -23.22 | -30.59 |
| Normalized Basic EPS | -3.29 | -6.21 | -10.97 | -14.87 | -19.48 |
| EPS Diluted | -16.57 | -9.93 | -16.98 | -23.22 | -30.59 |
| Normalized Diluted EPS | -3.29 | -6.21 | -10.97 | -14.87 | -19.48 |
| Average Basic Shares Outstanding | 7.97M | 3.78M | 2.67M | 1.83M | 1.18M |
| Average Diluted Shares Outstanding | 7.97M | 3.78M | 2.67M | 1.83M | 1.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |